376 related articles for article (PubMed ID: 11270251)
21. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
[TBL] [Abstract][Full Text] [Related]
22. Lessons learned from 20 years of newborn screening for cystic fibrosis.
Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
[TBL] [Abstract][Full Text] [Related]
23. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
[TBL] [Abstract][Full Text] [Related]
24. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
[TBL] [Abstract][Full Text] [Related]
25. Newborn Screening for Cystic Fibrosis in California.
Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L;
Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590
[TBL] [Abstract][Full Text] [Related]
26. Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis.
Ooi CY; Sutherland R; Castellani C; Keenan K; Boland M; Reisman J; Bjornson C; Chilvers MA; van Wylick R; Kent S; Price A; Mateos-Corral D; Hughes D; Solomon M; Zuberbuhler P; Brusky J; Durie PR; Ratjen F; Gonska T
BMC Pediatr; 2019 Oct; 19(1):369. PubMed ID: 31640630
[TBL] [Abstract][Full Text] [Related]
27. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
Padoan R; Bassotti A; Seia M; Corbetta C
Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
[TBL] [Abstract][Full Text] [Related]
28. Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years.
Lundman E; Gaup HJ; Bakkeheim E; Olafsdottir EJ; Rootwelt T; Storrøsten OT; Pettersen RD
J Cyst Fibros; 2016 May; 15(3):318-24. PubMed ID: 26795017
[TBL] [Abstract][Full Text] [Related]
29. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
[TBL] [Abstract][Full Text] [Related]
30. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
[TBL] [Abstract][Full Text] [Related]
31. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening.
Kay DM; Langfelder-Schwind E; DeCelie-Germana J; Sharp JK; Maloney B; Tavakoli NP; Saavedra-Matiz CA; Krein LM; Caggana M; Kier C;
Pediatr Pulmonol; 2015 Aug; 50(8):771-80. PubMed ID: 26098992
[TBL] [Abstract][Full Text] [Related]
32. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
[TBL] [Abstract][Full Text] [Related]
33. The CF-CIRC study: a French collaborative study to assess the accuracy of cystic fibrosis diagnosis in neonatal screening.
Sermet-Gaudelus I; Roussel D; Bui S; Deneuville E; Huet F; Reix P; Bellon G; Lenoir G; Edelman A
BMC Pediatr; 2006 Oct; 6():25. PubMed ID: 17018149
[TBL] [Abstract][Full Text] [Related]
34. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
[TBL] [Abstract][Full Text] [Related]
35. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
[TBL] [Abstract][Full Text] [Related]
36. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
[TBL] [Abstract][Full Text] [Related]
37. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
Ellery KM; Kopp B; Conwell DL; Gariepy C
Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
[TBL] [Abstract][Full Text] [Related]
38. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
[TBL] [Abstract][Full Text] [Related]
39. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.
Audrézet MP; Munck A; Scotet V; Claustres M; Roussey M; Delmas D; Férec C; Desgeorges M
Genet Med; 2015 Feb; 17(2):108-16. PubMed ID: 25122143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
